HauserSLKapposLMontalbanX, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology2021; 97: e1546–e1559.
2.
HauserSLBar-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383: 546–557.
3.
ChisariCGSgarlataEArenaS, et al. Rituximab for the treatment of multiple sclerosis: A review. J Neurol2022; 269: 159–183.
4.
LunaGAlpingPBurmanJ, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol2020; 77: 184–191.
5.
Simpson-YapSDe BrouwerEKalincikT, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology2021; 97: e1870–e1885.
6.
VollmerBLWallachAICorboyJR, et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol2020; 7: 1477–1487.
7.
Bar-OrACalkwoodJCChognotC, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology2020; 95: e1999–e2008.
8.
DisantoGSaccoRBernasconiE, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol2021; 78: 1529–1531.
9.
van KempenZLTooropAASellebjergF, et al. Extended dosing of monoclonal antibodies in multiple sclerosis. Mult Scler. 2021 Dec 24. doi: 10.1177/13524585211065711
10.
SabatinoJJJrZamvilSSHauserSL.B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med2019; 9: a032037.
